Article Text

Download PDFPDF
EMA suspends licence for ingenol mebutate (Picato)


Overview of: Medicines and Healthcare products Regulatory Agency. Ingenol mebutate gel (Picato▼): suspension of the licence due to risk of skin malignancy. Drug Safety Update 2020;13(7):1.

  • adherence
  • adverse effects

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.